The Supreme Court’s ruling this week in Prometheus vs Mayo that medical tests relying on correlations between drug dosages and treatment are non-patentable portends a dramatic and frightening reduction in patent protection for innovations in the life sciences and bio-technology industries – and beyond. The Court held that San Diego-based Prometheus Laboratories’ patent claim for … Continue reading “The Supreme Court’s Bad Precedent for Innovation”
Author: Robert Sachs
Robert R. Sachs is a Partner with Fenwick & West, LLP and a part of their Intellectual Property Group. He represents software and healthcare IT companies. He is the primary patent evaluator for various patent pools on today's most important audio, video, and communications technologies.